Evolving Legislation Associated with Fluorinated Hydrocarbon Propellants used in Metered Dose Inhalers
Hardwick M.
Respiratory Drug Delivery 2022. Volume , 2022: 55-64.
Abstract:
The recent observations of increased global warming and consequent climate impact are prompting further legislative action to review existing global accords and the associated regional legislation enacted to limit the emission of greenhouse gases. An overall reduction of greenhouse gas (GHG) emissions is central to individual, institutional and regional net zero ambitions. The contribution hydrofluorocarbons (HFCs) make to overall GHG emissions has led to their control and phasedown, and legislation continues to evolve around the globe.
In the context of the use of HFCs as medical propellants for pressurized metered dose inhalers (pMDIs), it is essential to ensure that the primary goal of supporting asthma and chronic obstructive pulmonary disease (COPD) patients to achieve and maintain symptom control, using appropriate and preferred medicine and inhaler delivery platforms, remains central to the ongoing discussion.
This article aims to provide an overview of the latest legislative developments and highlight gaps and opportunities for further dialogue.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
